EXPERIENCE WITH THE ANTICOAGULANT, MARCUMAR*

ANTICOAGULANT therapy is becoming increasingly important in the pre-vention and treatment of thrombo-embolic disease. Various investigators, in a search for an "ideal anticoagulant/ ' have expressed preferences for one or the other of several drugs of this type which are available commercially or experimentally. Recently many investigators have favored phenindione (Hedulin) as the "anticoagulant of choice.''x Among the anticoagulant drugs employed in our clinic since 1943 were bishydroxycoumarin (Dicumarol), cyclocumarol (Cumopyran), ethyl bis-coumacetate (Tromexan ethyl acetate), phenindione (Hedulin), diphena-dione (Dipaxin) and, more recently, phenprocoumon (Marcumar).f We were greatly impressed with the superiority of phenprocoumon with respect to greater predictability of results and better maintenance of prothrombin levels as compared with the other anticoagulants studied, and therefore wish to present our findings and observations. Marcumar (3-(l ^phenyl-propyl)4-hydroxy-coumar in) was described a